Rosa & Co. LLC
, a drug development consulting firm, has acquired the consulting service business of Entelos Holdings, Inc
., which conducts mechanistic, physiologic, in silico modeling projects for customers for pharmaceutical research and development. The acquisition expands Rosa's presence in quantitative systems pharmacology and modeling and simulation research services and adds expertise in cardiovascular, immunology, and metabolism biology, and human nutrition.
The acquisition also allows Entelos' clients to access Rosa's PhysioPD Research Platforms, which employ a user-friendly, open-architecture modeling and simulation system that is interoperable with commonly used third-party software.
"We are thrilled to further strengthen our expertise in these key areas, and have the opportunity to offer our proven approach to an expanded client base,” said chief executive officer of Rosa, Ron Beaver, Ph.D."